Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

特奈特普酶 医学 溶栓 纤溶剂 优势比 组织纤溶酶原激活剂 冲程(发动机) 单中心 瑞替普酶 内科学 心脏病学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Agnete Teivane,Kristaps Jurjāns,Jānis Vētra,Jekaterina Grigorjeva,Karlis Kupcs,Rytis Masiliūnas,Evija Miglāne
出处
期刊:Medicina-lithuania [Multidisciplinary Digital Publishing Institute]
卷期号:58 (9): 1169-1169
标识
DOI:10.3390/medicina58091169
摘要

Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b-3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4-26) vs. 15 (2-31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b-3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17-0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Miller发布了新的文献求助10
刚刚
刚刚
金光一闪完成签到,获得积分10
刚刚
qdange完成签到,获得积分10
刚刚
花花完成签到,获得积分10
刚刚
量子世界小居民完成签到,获得积分20
刚刚
刚刚
justonce发布了新的文献求助10
1秒前
1秒前
月光族完成签到,获得积分10
1秒前
温暖的问候完成签到,获得积分10
1秒前
端庄的小翠完成签到,获得积分10
2秒前
亢kxh完成签到,获得积分10
2秒前
polarisier发布了新的文献求助10
2秒前
细腻的蜗牛完成签到,获得积分10
2秒前
典雅又夏完成签到,获得积分10
2秒前
3秒前
葛稀完成签到,获得积分10
3秒前
3秒前
阿狸a完成签到,获得积分10
3秒前
4秒前
丫丫完成签到,获得积分10
4秒前
math-naive完成签到,获得积分10
5秒前
5秒前
PHD满完成签到,获得积分10
5秒前
星辰大海应助李安全采纳,获得10
5秒前
如风随水发布了新的文献求助10
5秒前
贺梦妍发布了新的文献求助10
5秒前
Ava应助euphoria采纳,获得10
6秒前
细心的雁玉完成签到,获得积分10
7秒前
灰澈大大完成签到 ,获得积分10
7秒前
7秒前
努力学习才能找到工作完成签到 ,获得积分10
7秒前
落后的听双完成签到,获得积分10
8秒前
Lina HE完成签到 ,获得积分10
8秒前
8秒前
Wind应助yar采纳,获得20
8秒前
Yang完成签到,获得积分10
8秒前
852应助大意的怀柔采纳,获得10
8秒前
yanzilin发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Fermented Coffee Market 2000
PARLOC2001: The update of loss containment data for offshore pipelines 500
Critical Thinking: Tools for Taking Charge of Your Learning and Your Life 4th Edition 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
Vertebrate Palaeontology, 5th Edition 340
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5256834
求助须知:如何正确求助?哪些是违规求助? 4419081
关于积分的说明 13754519
捐赠科研通 4292230
什么是DOI,文献DOI怎么找? 2355404
邀请新用户注册赠送积分活动 1351852
关于科研通互助平台的介绍 1312634